← Back to all trials
Recruiting
NCT07535606
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Conditions: Healthy Volunteers
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 44
Sponsor: Alnylam Pharmaceuticals
Location: Clinical Trial Site London
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
Eligibility Criteria
Inclusion Criteria:
* Is willing and able to complete all study assessments
Exclusion Criteria:
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>upper limit of normal (ULN)
* Has total bilirubin \>ULN
* Has no history of invasive infection by an encapsulated organism
* Has no known complement or immunologic deficiency
Source: ClinicalTrials.gov (NCT07535606). StuddyBuddy aggregates publicly available trial information.
